Access Purchased Content

Home » Authors » Talia Puzantian, PharmD, BCPP

Talia Puzantian, PharmD, BCPP

Talia Puzantian, PharmD, BCPP

Deputy Editor,

Articles

Products

ARTICLES

Fact Sheet

Bupropion SR (Zyban) Fact Sheet

January 1, 2026

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

DSM-5: “Problematic pattern” of tobacco use leading to “significant distress” that lasts at least 12 months.

Fact Sheet

Smoking Cessation

January 1, 2026

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

DSM-5: “Problematic pattern” of tobacco use leading to “significant distress” that lasts at least 12 months.

Fact Sheet

NALTREXONE (ReVia, Vivitrol) Fact Sheet [G]

January 1, 2026

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Naltrexone is the first-line medication for alcohol use disorder (AUD) and is also approved for opioid use disorder (OUD).

Fact Sheet

NALOXONE (Kloxxado, Narcan Nasal Spray, Rextovy, Rezenopy, RiVive, Zimhi) Fact Sheet [G]

January 1, 2026

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Nalmefene is an opioid antagonist that has higher affinity for opioid receptors and is more potent and longer acting than naloxone.

Fact Sheet

Nalmefene (Opvee) Fact Sheet

January 1, 2026

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Nalmefene is an opioid antagonist that has higher affinity for opioid receptors and is more potent and longer acting than naloxone.

Fact Sheet

Lofexidine (Lucemyra) Fact Sheet

January 1, 2026

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Lofexidine is an alpha-2 agonist (similar to clonidine and guanfacine) that is used to reduce the intensity of opioid withdrawal symptoms.

Fact Sheet

Buprenorphine/Naloxone (Bunavail, Suboxone, Zubsolv) Fact Sheet

January 1, 2026

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Buprenorphine/naloxone is the definitive partial agonist treatment for opioid use disorder (OUD).

Treatment Algorithm

Opioid Use Disorder Treatment Algorithm

January 1, 2026

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Opioid Use Disorder Treatment Algorithm

Fact Sheet

Blue Light Blocking Glasses Fact Sheet

January 1, 2026

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Blue light blocking glasses are a simple, safe, and remarkably effective adjunctive treatment for bipolar mania and insomnia.

Fact Sheet

Weight Gain Fact Sheet

January 1, 2026

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Medication-related weight gain often presents with food cravings and bingeing.

View All Articles by Talia Puzantian, PharmD, BCPP

Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)
Updated 2026 prescriber's guide.
READ MORE

General Psychiatry
KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything
Read More

Psychology and Social Work
Treating BPD Series, Episode 2: Transference-Focused Psychotherapy—From Splitting to Coherence with Frank Yeomans, MD, PhD
In this episode, Dr. Frank Yeomans offers a deep dive into the theory and clinical practice of TFP as a treatment for Borderline Personality Disorder.
Listen now

Join Our Writing Team
July 18, 2024
Insights About a Rare Transmissible Form of Alzheimer's Disease
February 9, 2024
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners
May 24, 2024

Join Our Writing Team
July 18, 2024
Insights About a Rare Transmissible Form of Alzheimer's Disease
February 9, 2024
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners
May 24, 2024

Join Our Writing Team
July 18, 2024
Insights About a Rare Transmissible Form of Alzheimer's Disease
February 9, 2024
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners
May 24, 2024